What question did this study set out to answer?

To evaluate the efficacy and tolerate of tradipitant, a neurokinin-1 receptor antagonist, for motion sickness prevention.

Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows tradipitant prevents motion sickness symptoms in adults, suggesting a novel treatment option.

To evaluate the efficacy and tolerate of tradipitant, a neurokinin-1 receptor antagonist, for motion sickness prevention.
Two phase 3 pivotal trials: Motion Syros (N=365) and Motion Serifos (N=316)
Participants were randomly assigned to receive either tradipitant or placebo in a double-blinded manner
Primary outcome measured was incidence of vomiting associated with motion sickness.
In Motion Syros, tradipitant 170 mg had an incidence of vomiting at 18.3% vs placebo at 44.3% (P=0.00002)
In Motion Serifos, the incidence for 170 mg tradipitant was 10.4% compared to 37.7% for placebo (P=0.0014)
Tradipitant was well-tolerated with no serious adverse events reported.

Nguyen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows tradipitant prevents motion sickness symptoms in adults, suggesting a novel treatment option.

To evaluate the efficacy and tolerate of tradipitant, a neurokinin-1 receptor antagonist, for motion sickness prevention.
Two phase 3 pivotal trials: Motion Syros (N=365) and Motion Serifos (N=316)
Participants were randomly assigned to receive either tradipitant or placebo in a double-blinded manner
Primary outcome measured was incidence of vomiting associated with motion sickness.
In Motion Syros, tradipitant 170 mg had an incidence of vomiting at 18.3% vs placebo at 44.3% (P=0.00002)
In Motion Serifos, the incidence for 170 mg tradipitant was 10.4% compared to 37.7% for placebo (P=0.0014)
Tradipitant was well-tolerated with no serious adverse events reported.

Nguyen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark